Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Active not recruiting 3Unknown 1Terminated 1Completed 1

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

CNS 3

Conditions

Brain Neoplasms 23Prostatic Neoplasms 19Carcinoma, Non-Small-Cell Lung 16Lung Neoplasms 11Neoplasm Metastasis 8Melanoma 6Breast Neoplasms 6Squamous Cell Carcinoma of Head and Neck 4Pancreatic Neoplasms 4Carcinoma, Renal Cell 4Small Cell Lung Carcinoma 3Meningioma 3Urinary Bladder Neoplasms 2Sarcoma 2Prostate Adenocarcinoma 2Neoplasms 2Kidney Neoplasms 2Head and Neck Neoplasms 2Glioblastoma 2Gastrointestinal Neoplasms 2Colorectal Neoplasms 2Adenocarcinoma of Lung 2Uterine Cervical Neoplasms 1Urologic Neoplasms 1Urologic Diseases 1Urinary Bladder Diseases 1Triple Negative Breast Neoplasms 1Thyroid Neoplasms 1Stomach Neoplasms 1Stage II Prostate Adenocarcinoma AJCC v7 1

Interventions

Radiosurgery 3pembrolizumab 2Nivolumab 2Ipilimumab 2CTLA-4 Antigen 2ribociclib 1lutetium Lu 177 dotatate 1abemaciclib 1Specimen Handling 1Mental Status and Dementia Tests 1Magnetic Resonance Spectroscopy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Active not recruiting × Meningioma × Radiosurgery × Clear all
NCT03604978 2026-05-13

Nivolumab and Multi-fraction Stereotactic Radiosurgery With or Without Ipilimumab in Treating Patients With Recurrent Grade II-III Meningioma

National Cancer Institute (NCI)

Phase 1/2 Active not recruiting
38 enrolled
CNS

Meningioma

NCT06466720 2026-05-04

CoDeB-Rad

University of Nottingham

Active not recruiting
80 enrolled
CNS

Brain Neoplasms, Meningioma, Cognitive Dysfunction

NCT04659811 2026-04-15

Stereotactic Radiosurgery and Immunotherapy (Pembrolizumab) for the Treatment of Recurrent Meningioma

University of California, San Francisco

Phase 2 Active not recruiting
35 enrolled
CNS

Meningioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡